Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rachel Triche

Foot and Ankle Surgery Santa Monica, CA Medical Doctor

NPI 1215084009 CMS profile 281497

2020 Santa Monica Blvd Ste 400, Santa Monica, CA 90404

Open in the dashboard

General payments

$9,288

62 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rachel Triche of Santa Monica, CA is reported in the CMS Open Payments database as having received $9,288 across 62 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 51st percentile of Foot and Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $114 2
2024 General $312 6
2023 General $2,138 21
2022 General $1,501 17
2021 General $165 5
2020 General $4,131 7
2019 General $928 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rachel Triche
  • Foot and Ankle Surgery median
  • Middle half of Foot and Ankle Surgery
  • National median

In program year 2025, general payments to Rachel Triche were reported at $114. Among 650 Foot and Ankle Surgery profiles paid that year, the median was $1,183 and the middle half received between $267 and $6,309.

Show as a table
Year Rachel Triche Foot and Ankle Surgery median Middle half National median
2019 $928 $1,327 $279–$5,421 $163
2020 $4,131 $795 $121–$3,473 $114
2021 $165 $1,289 $201–$4,963 $132
2022 $1,501 $1,539 $270–$6,067 $149
2023 $2,138 $1,117 $257–$5,264 $160
2024 $312 $1,064 $235–$4,944 $164
2025 $114 $1,183 $267–$6,309 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Arthrex, Inc. $5,636 13 payments
  2. Micromed Inc $1,222 3 payments
  3. Gemini Medical LLC $852 1 payment
  4. Bioventus LLC $768 33 payments
  5. Saxum Surgical, Inc. $583 6 payments
  6. DePuy Synthes Sales Inc. $144 2 payments
  7. Avanos Medical $41 1 payment
  8. Stryker Corporation $14 1 payment
  9. Dynasplint Systems Inc. $13 1 payment
  10. Djo, LLC $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,000 1 payment
  2. Food and Beverage $2,157 56 payments
  3. Education $2,052 2 payments
  4. Travel and Lodging $1,079 3 payments
Products named General payments · program years 2019–2025
  1. Exogen Ultrasound Bone Healing System Not Applicable $507 21 payments
  2. Exogen $124 6 payments
  3. NA $120 1 payment
  4. DYNATAPE $120 1 payment
  5. TWISTR $120 1 payment
  6. DYNACORD $120 1 payment
  7. TRUESPAN ORTHOCORD $120 1 payment
  8. EXOGEN ULTRASOUND BONE HEALING SYSTEM Devices $62 3 payments
  9. Durolane Orthopedics/Orthopedic Surgery $47 2 payments
  10. Durolane Orthopedics/Orthopedic Surgery $27 1 payment
  11. Other $64 4 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

49

Median for Sports Medicine: 144

Drug cost

$299

Median for Sports Medicine: $1,027

Branded share of claims

0%

Median for Sports Medicine: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 12 $186
Meloxicam Generic 37 $113

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,691 Part D prescribers listed as Sports Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 65 billing codes

Paid by Medicare

$134,599

Of which drugs: $2,909

Medicare patients

492

Average age 75

Services billed

1,893

323 women, 169 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 68%
High blood pressure 57%
Ischemic heart disease 30%
Osteoporosis 26%
Diabetes 19%
Depression 18%
Cancer 16%
Atrial fibrillation 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 25 54 $40

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

62 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record